ITCI vs. HALO

In the year-to-date period, ITCI achieves a 57.89% return, which is significantly higher than HALO's 26.52% return. Over the past 10 years, ITCI has outperformed HALO with an annualized return of 20.71%, while HALO has yielded a comparatively lower 15.11% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Intra-Cellular Therapies, Inc. (ITCI) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ITCI Sharpe Ratio is 1.72, which is comparable to the HALO Sharpe Ratio of 1.35. The chart below compares the historical Sharpe Ratios of ITCI and HALO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ITCI nor HALO has paid dividends to shareholders.

The maximum ITCI drawdown since its inception was -87.64%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for ITCI and HALO. For additional features, visit the drawdowns tool.

The current volatility for Intra-Cellular Therapies, Inc. (ITCI) is 0.11%, while Halozyme Therapeutics, Inc. (HALO) has a volatility of 12.40%. This indicates that ITCI experiences smaller price fluctuations and is considered to be less risky than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.